Skip to search formSkip to main contentSkip to account menu

Levodopa

Known as: beta-(3,4-Dihydroxyphenyl)-L-alanine, 3,4-Dihydroxy-L-phenylalanine, .beta.-(3,4-Dihydroxyphenyl)-L-alanine 
An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and… 
National Institutes of Health

Related topics

Related topics

37 relations

Narrower (18)

2,4,5-trihydroxyphenylalanine quinone2,4-dihydroxyphenylalanine3,4,6-trihydroxyphenylalanine quinone3-O-methyl-6-fluoro-dopa

Broader (2)

Antiparkinson AgentsDopa
Carbidopa / LevodopaCarbidopa 10 MG / Levodopa 100 MG Disintegrating Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral TabletCarbidopa 10 MG / Levodopa 100 MG Oral Tablet [Sinemet]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost over time, and abnormal… 
Review
2005
Review
2005
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Levodopa therapy, as originally established by George Cotzias [2, 3], is the most powerful treatment for Parkinson’s disease (PD… 
Highly Cited
2005
Highly Cited
2005
Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations that could be in part due to central… 
Highly Cited
2002
Highly Cited
2002
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
In an attempt to define clinically relevant models of akinesia and dyskinesia in 6‐hydroxydopamine (6‐OHDA)‐lesioned rats, we… 
Highly Cited
2000
Highly Cited
2000
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
CONTEXT Pramipexole and levodopa both ameliorate the motor symptoms of early Parkinson disease (PD), but no controlled studies… 
Highly Cited
2000
Highly Cited
2000
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
OBJECTIVES: To examine the rate and predictors of nursing home placement in patients with Parkinson's disease. 
Review
1999
Review
1999
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint
Levodopa (in combination with a peripheral dopadecarboxylase inhibitor) substantially improves the quality of life of patients… 
Highly Cited
1996
Highly Cited
1996
Augmentation of the restless legs syndrome with carbidopa/levodopa.
Dopaminergic agents and carbidopa/levodopa have become the preferred treatment for both the restless legs (RL) syndrome and for… 
Highly Cited
1979
Highly Cited
1979
Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey.
Depletion of dopamine in a circumscribed area of association cortex in rhesus monkeys produces an impairment in spatial delayed… 
Highly Cited
1969
Highly Cited
1969
Modification of Parkinsonism--chronic treatment with L-dopa.
Abstract Slowly increasing oral doses of L-3,4-dihydroxyphenylalanine (L-dopa) induced at least partial improvement of some… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)